Physician profile
Jonathan Malka
NPI 1558532275
$32,002.28
in general payments reported to CMS, 2019-2025
26 companies · $12K in 2025
The $12K reported for 2025 was more than what 88% of Pediatric Allergy/Immunology providers received nationally (typical 2025 total: $375).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $349 · 2020: $55.39 · 2021: $108 · 2022: $171 · 2023: $656 · 2024: $18K · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $24K · Travel and Lodging: $3,096 · Consulting Fee: $2,532 · Food and Beverage: $1,581 · Education: $165 · Long Term Medical Supply Or Device Loan: $19.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $23,925.00 |
| Travel and Lodging | $3,095.87 |
| Consulting Fee | $2,531.75 |
| Food and Beverage | $1,580.93 |
| Education | $165.35 |
| Long Term Medical Supply Or Device Loan | $19.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alk-Abello, INC | $27,830.78 | 2023-2025 | Odactra, Grastek, Ragwitek |
| Regeneron Healthcare Solutions, INC. | $3,106.02 | 2019-2025 | Dupixent |
| Circassia INC. | $139.00 | 2019-2023 | Niox |
| Kaleo, INC. | $123.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $115.29 | 2019-2023 | Nucala |
| Ars Pharmaceuticals Operations, INC. | $84.45 | 2025 | Neffy |
| Amgen INC. | $75.45 | 2022 | |
| Cranial Technologies, INC | $63.88 | 2019-2023 | Doc Band |
| Takeda Pharmaceuticals U.S.A., INC. | $52.46 | 2024 | Eohilia |
| Novartis Pharmaceuticals Corporation | $46.91 | 2024 | |
| Pfizer INC. | $41.38 | 2019 | |
| Sobi, INC | $29.49 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $27.30 | 2024 | Tezspire |
| Biomarin Pharmaceutical INC. | $25.29 | 2025 | Voxzogo 1.2mg |
| Biocryst US Sales Co., LLC | $24.05 | 2024 | Orladeyo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $23.87 | 2021 | |
| Greer Laboratories, INC. | $23.85 | 2025 | Oralair |
| Sanofi Pasteur INC. | $22.11 | 2024 | |
| Abbvie INC. | $22.06 | 2021 | |
| Ironshore Pharmaceuticals INC. | $19.99 | 2021 | |
| Baxter Healthcare | $19.41 | 2023 | Hillrom - Cp 150 Resting Electrocardiograph |
| Merck Sharp & Dohme LLC | $19.16 | 2023 | Proquad, Vaxneuvance, Vaxelis |
| Cipher Pharmaceuticals US LLC | $19.04 | 2025 | Natroba, Spinosad |
| Aimmune Therapeutics, INC. | $17.99 | 2020 | |
| Amneal Pharmaceuticals LLC | $15.94 | 2019 | |
| Phadia US INC. | $13.36 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Malka listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.